Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIGIN EXTEND: Long-Term Safety and Efficacy of Atacicept in IgAN
NCT06674577Phase 2Enrolling by invitation
- Sponsor
- Vera Therapeutics
- Start
- Dec 2024
- Primary completion
- May 2031
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of atacicept in IgA nephropathy (IgAN), sponsored by Vera Therapeutics. Started Dec 2024; status: enrolling by invitation.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06674577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674577.